Entrada Therapeutics (TRDA) Tax Provisions (2023 - 2026)

Entrada Therapeutics (TRDA) posted quarterly Tax Provisions of $38000.0 for Q1 2026, down 62.0% quarter-over-quarter from $100000.0 in Q4 2025.

Entrada Therapeutics (TRDA) Tax Provisions (2023 - 2026) Analysis & Trends

Entrada Therapeutics' Tax Provisions history runs 4 years deep, the most recent figure standing at $38000.0 for Q1 2026.

In Q1 2026, Tax Provisions changed N/A year-over-year to $38000.0; the TTM figure through Mar 2026 stood at $992000.0 (up 206.67% YoY), while the FY2025 annual figure was $900000.0, up 4.77% from the prior year.
Tax Provisions for Q1 2026 stood at $38000.0, down from $100000.0 in the prior quarter.
The five-year high for Tax Provisions was $18.7 million in Q4 2023, with the low at -$17.4 million in Q3 2023.
The 4-year median for Tax Provisions is $427000.0 (2025), against an average of $1.7 million.
The sharpest annual moves came in 2024 and 2025: Tax Provisions sank 110.0% in 2024, then surged 135.16% in 2025.
Entrada Therapeutics' Tax Provisions stood at $18.7 million in 2023, then tumbled by 110.0% to -$1.9 million in 2024, then soared by 105.35% to $100000.0 in 2025, then plunged by 62.0% to $38000.0 in 2026.
Business Quant data shows TRDA's Tax Provisions at $38000.0 in Q1 2026, $100000.0 in Q4 2025, and $654000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	59.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	75.45 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	267.73
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.31 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	1.90 Mn
10	Entrada Therapeutics	290.47 Mn	290.47 Mn	-	35,000.00

Download Data